After demonstrating, in silico and through IHC analysis on an independent case cohort, that SLFN11 is expressed not only in cancer cells, but also in TILs, in macrophages, and in other immune cell subpopulations, we wondered how SLFN11 expression in HGSOC is correlated with biologically selected, well-established immune signatures representing hallmarks of immune activity, such as IFN-α and -γ signaling and STAT1 activation (27–29), MHC I and MHC II upregulation (30, 31), antigen presenting machinery (32), immunologic constant of rejection (33–37), and immunogenic cell death (38). This evidence concerns the gene IFNA1 and cancer.